Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutimlimab Extension Study for CAD in Japan
NCT05132127Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sutimlimab in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events up to 49 weeks and Number of Participants With Treatment-emergent Adverse Events of Special Interest up to 49 weeks. Started Nov 2021; status: completed.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05132127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132127.